Sachi Bio plans to utilize brain organoids in microgravity, which is the state of apparent weightlessness experienced during free fall or orbital motion. Microgravity causes significant changes in various observable phenomena in physical and life sciences, enabling researchers to explore biology in ways not achievable on Earth. The International Space Station offers a continuous microgravity setting for testing the impact of Sachi Bio's Nanoligomer-drugs on major neurodegenerative diseases—Alzheimer’s, Parkinson’s, and ALS; as well as an aggressive form of brain cancer, Glioblastoma multiforme. The findings could contribute to the progress of developing novel treatments for patients on Earth.
Sachi Bio is at the forefront of groundbreaking research by harnessing the unique environment of microgravity for studying brain organoids. Microgravity, characterized by apparent weightlessness in free fall or orbital motion, presents a wealth of opportunities for scientists to delve into the intricacies of physical and life sciences.
The distinct conditions of microgravity lead to significant alterations in observable phenomena, offering a novel perspective on various scientific inquiries that are otherwise limited on Earth. By leveraging the International Space Station's continuous microgravity environment, Sachi Bio aims to conduct experiments testing the effects of new drugs on debilitating neurodegenerative diseases—Alzheimer’s, Parkinson’s, and ALS; as well as a rare but aggressive form of brain cancer, Glioblastoma multiforme.
Sachi Bio sent nearly 600 patient based brain organoids in to outer space to evaluate a range of novel Nanoligomer treatments. This pioneering research endeavor holds immense promise for advancing our understanding of these conditions and potentially revolutionizing treatment approaches. The findings from these experiments have the potential to unveil crucial insights that could pave the way for the development of innovative therapies to benefit patients suffering from these diseases back on Earth.
The utilization of brain organoids in microgravity represents a cutting-edge approach that has the potential to reshape the landscape of neuroscientific research. Through this innovative methodology, Sachi Bio is poised to make significant strides in unraveling the complexities of neurodegenerative diseases and exploring new avenues for therapeutic interventions. The implications of this research extend far beyond the confines of space, offering hope for improved healthcare outcomes and enhanced quality of life for individuals affected by these debilitating conditions.
Recent publications on this topic from Sachi Bio:
Sadhana Sharma, Vincenzo S. Gilberto, Jon Rask, Anushree Chatterjee*, Prashant Nagpal* (2024). ACS Chemical Neuroscience 15, 16, 3009–3021.